• Topical pain relief

Ztlido Generic Name & Formulations

General Description

Lidocaine 1.8%; topical system.

Pharmacological Class

Topical anesthetic.

How Supplied



Generic Availability


Ztlido Indications


Postherpetic neuralgia (PHN).

Ztlido Dosage and Administration


Apply to intact skin, covering most painful area. To adjust dose, cut patches before removing release liner. Remove if irritation or burning occurs; do not reapply until irritation subsides. May apply up to 3 patches at once for up to 12hrs of a 24-hour period. Hepatic impairment or debilitated: use smaller treatment areas.


Not established.

Ztlido Contraindications

Not Applicable

Ztlido Boxed Warnings

Not Applicable

Ztlido Warnings/Precautions


Do not apply to broken or inflamed skin. Avoid eyes, longer duration of application, and application of more than 3 patches. Avoid direct external heat sources (eg, heating pads, electric blankets). Accidental exposure to children and pets. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Potential cross-sensitivity with allergy to PABA derivatives (eg, procaine, tetracaine, benzocaine). Hepatic disease. Small patients. Pregnancy. Nursing mothers.

Ztlido Pharmacokinetics

See Literature

Ztlido Interactions


Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others. Toxicity may be potentiated by Class I antiarrhythmics (eg, tocainide, mexiletine). Additive effects with other products containing local anesthetics.

Ztlido Adverse Reactions

Adverse Reactions

Applications site reactions (eg, irritation, erythema, pruritus); hypersensitivity reactions.

Ztlido Clinical Trials

See Literature

Ztlido Note

Not Applicable

Ztlido Patient Counseling

See Literature